每年專案
個人檔案
學歷
- 2010 高雄醫學大學生物醫學研究所博士
- 2005 高雄醫學大學生物醫學研究所碩士
- 2004 高雄醫學大學生物醫學暨環境生物學系學士
經歷
- 2017- 臺北醫學大學生藥學研究所副教授
- 2016-2017 臺北醫學大學生技醫療產業研發博士學位學程助理教授
- 2015- 臺北醫學大學轉譯醫學博士學位學程助理教授
- 2013- 臺北醫學大學中草藥臨床藥物研發博士學位學程
- 2013- 臺北醫學大學臨床藥物基因體學暨蛋白質體學碩
- 2012-2017 臺北醫學大學生藥學研究所助理教授
- 2010-2011 高雄海洋科技大學水產養殖系兼任助理教授
獎項
- 2012 戰國策創業競賽 (特優獎)
- 2008 國家新創獎 (第一名)
指紋
- 6 類似的個人檔案
網路
專案
-
乳癌細胞α9尼古丁受體作為新穎靶向RNA奈米藥物與T細胞療法之臨床轉譯研究-開發抗α9尼古丁受體/抗CD3雙功能抗體以一步驟建構可高效標靶毒殺乳癌腫瘤之武裝型T細胞免疫療法(1/3)
8/1/20 → 7/1/21
研究計畫: A - 政府部門 › b - 科技部
-
-
-
-
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估-開發抗α9尼古丁受體/抗聚乙二醇雙功能抗體以提升奈米藥物之乳癌標靶療效(3/3)(相對補助)
8/1/19 → 7/31/20
研究計畫: A - 政府部門 › f - 其他(政府部門資助)
研究成果
-
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 九月 1 2020, 於: European Journal of Medicinal Chemistry. 201, 112404.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
-
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., 八月 1 2020, 於: European Journal of Medicinal Chemistry. 199, 112406.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯(Scopus) -
Downregulation of gap junctional intercellular communication and connexin 43 expression by bisphenol A in human granulosa cells
Lin, T. C., Wang, K. H., Chuang, K. H., Kao, A. P. & Kuo, T. C., 2020, (接受/付印) 於: Biotechnology and Applied Biochemistry.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Cheng, Y. A., Wu, T. H., Wang, Y. M., Cheng, T. L., Chen, I. J., Lu, Y. C., Chuang, K. H., Wang, C. K., Chen, C. Y., Lin, R. A., Chen, H. J., Liao, T. Y., Liu, E. S. & Chen, F. M., 八月 27 2020, 於: Journal of Nanobiotechnology. 18, 1, 118.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 三月 15 2020, 於: European Journal of Medicinal Chemistry. 190, 112086.研究成果: 雜誌貢獻 › 文章 › 同行評審
7 引文 斯高帕斯(Scopus)
資料集
-
Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Cheng, Y. (Contributor), Wu, T. (Contributor), Wang, Y. (Contributor), Cheng, T. (Contributor), Chen, I. (Contributor), Lu, Y. (Contributor), Chuang, K. (Contributor), Wang, C. (Contributor), Chen, C. (Contributor), Lin, R. (Contributor), Chen, H. (Contributor), Liao, T. (Contributor), Liu, E. (Contributor) & Chen, F. (Contributor), Unknown Publisher, 一月 1 2020
DOI: 10.6084/m9.figshare.c.5105096.v1, https://springernature.figshare.com/collections/Humanized_bispecific_antibody_mPEG_HER2_rapidly_confers_PEGylated_nanoparticles_tumor_specificity_for_multimodality_imaging_in_breast_cancer/5105096/1
資料集: Dataset
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Su, C. (Contributor), Chen, M. (Contributor), Chen, L. (Contributor), Ho, Y. (Contributor), Ho, H. (Contributor), Lin, S. (Contributor), Chuang, K. (Contributor) & Sheu, M. (Contributor), Unknown Publisher, 五月 2 2018
DOI: 10.6084/m9.figshare.6213620.v1, https://tandf.figshare.com/articles/Bispecific_antibodies_anti-mPEG_anti-HER2_for_active_tumor_targeting_of_docetaxel_DTX_-loaded_mPEGylated_nanocarriers_to_enhance_the_chemotherapeutic_efficacy_of_HER2-overexpressing_tumors/6213620/1
資料集: Dataset
-
Additional file 1 of Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Cheng, Y. (Contributor), Wu, T. (Contributor), Wang, Y. (Contributor), Cheng, T. (Contributor), Chen, I. (Contributor), Lu, Y. (Contributor), Chuang, K. (Contributor), Wang, C. (Contributor), Chen, C. (Contributor), Lin, R. (Contributor), Chen, H. (Contributor), Liao, T. (Contributor), Liu, E. (Contributor) & Chen, F. (Contributor), Unknown Publisher, 一月 1 2020
DOI: 10.6084/m9.figshare.12885938.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Humanized_bispecific_antibody_mPEG_HER2_rapidly_confers_PEGylated_nanoparticles_tumor_specificity_for_multimodality_imaging_in_breast_cancer/12885938/1
資料集: Dataset